EcoDrugPlus

Tyrosine Kinase With Immunoglobulin Like And Egf Like Domains 1

Ensembl ID : ENSFHEG00000001516
Gene Symbol: TIE1
3 Cross references
207 Possible Orthologues:

Tyrosine-Protein Kinase Jak2

Ensembl ID : ENSFHEG00000012363
Gene Symbol: LOC105932126
3 Cross references
198 Possible Orthologues:

Tyrosine-Protein Kinase Jak2-Like

Ensembl ID : ENSFHEG00000004327
Gene Symbol: LOC105937265
3 Cross references
194 Possible Orthologues:

Tyrosine-Protein Kinase Lyn-Like

Ensembl ID : ENSFHEG00000022231
Gene Symbol: LOC105936452
3 Cross references
196 Possible Orthologues:

Tyrosine-Protein Kinase Yes

Ensembl ID : ENSFHEG00000018541
Gene Symbol: LOC105920338
3 Cross references
197 Possible Orthologues:

Tyrosine-Protein Kinase Fyna

Ensembl ID : ENSFHEG00000009938
Gene Symbol: LOC105939053
3 Cross references
192 Possible Orthologues:

Uncharacterized Loc105915406

Ensembl ID : ENSFHEG00000010379
Gene Symbol: LOC105915406
2 Cross references
192 Possible Orthologues:

Uncharacterized Loc105933547

Ensembl ID : ENSFHEG00000000847
Gene Symbol: LOC105933547
2 Cross references
194 Possible Orthologues:

Utrophin

Ensembl ID : ENSFHEG00000000967
Gene Symbol: UTRN
4 Cross references
253 Possible Orthologues:

Vascular Endothelial Growth Factor A

Ensembl ID : ENSFHEG00000008991
Gene Symbol: VEGFA
3 Cross references
197 Possible Orthologues:

Vitamin D Receptor

Ensembl ID : ENSFHEG00000009605
Gene Symbol: VDR
3 Cross references
392 Possible Orthologues:

Vitamin D3 Receptor B

Ensembl ID : ENSFHEG00000006854
Gene Symbol: LOC105931721
3 Cross references
394 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).